• 46.2% clinical remission with rifamycin 1% topically acting gel vs 14.3% with placebo (p=0.0190). • The therapy represents a new non-immune suppressive treatment modality, designed to achieve delivery to the distal colon with a novel liquid to gel delivery system, and a neutral pH. • The results suggest that the anti-microbial properties of rifamycin may be positively affecting the gut microbiome and affecting host immune responses. • Phase 3 planning will be informed by FDA and EMA discussions • Investor call today at 4 pm CEST
Cosmo N.V. (“Cosmo”) today announced topline results from its Phase 2 study (EUCT number: 2023-506917-23-00) of rifamycin 1% topically acting gel in patients with mildly to moderately active distal ulcerative colitis (DUC) and ulcerative proctitis. The study was designed in line with the US Food and Drug Administration (FDA) guidance on the development of drug products for ulcerative colitis.1 The study met its primary endpoint, with a significantly greater proportion of patients treated with rifamycin 1% topically acting gel achieving clinical remission than with placebo.